Results 51 to 60 of about 756,250 (282)

A State-of-the-Art Review Exploring the Cardiovascular Outcomes of Renin-Angiotensin Inhibitors in Acute Kidney Injury

Cardiorenal Medicine
Background: Renin-angiotensin system (RAS) inhibitors, including ACE inhibitors, ARBs, and angiotensin receptor-neprilysin inhibitors (ARNIs), are essential in managing cardiovascular and renal diseases.
Farah Yasmin, Sharjeel Ahmad, Adina Jabeen, Abdul Moeed, Muhammad Sohaib Asghar, Afsana Ansari Shaik, Mohammed Mahmmoud Fadelallah Eljack, M. Chadi Alraies   +7 more
doaj   +1 more source

Possible therapeutic repositioning of valproic acid: From epileptic seizures to acute kidney injury

British Journal of Clinical Pharmacology, EarlyView.
Valproic acid, an anticonvulsant, may be repositioned to prevent acute kidney injury due to ischemia followed by reperfusion. It preserves renal functions, electrolyte homeostasis and active sodium transport in kidney tubules, and blocks the onset of hypertension.
Danilo Alves‐Bezerra, Luiza B. Negreiros, Amaury Pereira‐Acácio, Isadora G. Almeida, João P. M. Veloso‐Santos, Jarlene A. Lopes, Glória Costa‐Sarmento, Humberto Muzi‐Filho, Adalberto Vieyra   +8 more
wiley   +1 more source

New Approaches to Blockade of the Renin–Angiotensin–Aldosterone System: Mineralocorticoid-Receptor Blockers Exert Antihypertensive and Renoprotective Effects Independently of the Renin–Angiotensin System

Journal of Pharmacological Sciences, 2010
The role of angiotensin II in mediating hypertension and renal diseases is well documented, and inhibition of the renin–angiotensin–aldosterone system elicits antihypertensive and renoprotective effects.
Akira Nishiyama, Koichi Hasegawa, Suwarni Diah, Hirofumi Hitomi   +3 more
doaj   +1 more source

Hypertension in obesity: A focus on individualized pharmacotherapy and the role of body composition, on behalf of the European Society of Hypertension Working Group on Diabetes and Metabolic Risk Factors and Working Group on Lifestyle, Cardiovascular Pharmacotherapy and Adherence

British Journal of Clinical Pharmacology, EarlyView.
Hypertension in obesity represents a major global health challenge, closely linked to the global epidemics of obesity, type 2 diabetes and metabolic dysfunction. Excess adiposity contributes to elevated blood pressure through multiple, interrelated mechanisms, including activation of the renin–angiotensin–aldosterone system, sympathetic nervous system ...
Christina Antza, Andrej Belancic, Jens Jordan, Alberto Esteban, Anna Oliveras, Ryan McNally, Panagiota Anyfanti, Jorie Versmissen, María S. Fernández‐Alfonso, Vasilios Kotsis, Thomas Weber, Alexandre Persu, Reinhold Kreutz   +12 more
wiley   +1 more source

Generic names and doses of renin-angiotensin system inhibitors that prescribed at discharge in propensity-score matched cohort.

, 2023
Generic names and doses of renin-angiotensin system inhibitors that prescribed at discharge in propensity-score matched cohort.
Jin-Yong Hwang (849405), Seung-Jae Joo (3620240), Joon-Hyouk Choi (14768868), Ki Yung Boo (6528530), Seung-Ho Hur (736905), Myung Ho Jeong (8201055), Song-Yi Kim (4456264), Jae-Geun Lee (11917219)   +7 more
core   +1 more source

The Effect of Antihypertensive Medications on Testing for Primary Aldosteronism

Frontiers in Pharmacology, 2021
Primary aldosteronism (PA) is a potentially curable form of secondary hypertension caused by excessive renin-independent aldosterone secretion, leading to increased target organ damage and cardiovascular morbidity and mortality.
Piotr Jędrusik, Bartosz Symonides, Jacek Lewandowski, Zbigniew Gaciong   +3 more
doaj   +1 more source

Systemic aging fuels heart failure: Molecular mechanisms and therapeutic avenues

ESC Heart Failure, Volume 12, Issue 2, Page 1059-1080, April 2025.
Abstract Systemic aging influences various physiological processes and contributes to structural and functional decline in cardiac tissue. These alterations include an increased incidence of left ventricular hypertrophy, a decline in left ventricular diastolic function, left atrial dilation, atrial fibrillation, myocardial fibrosis and cardiac ...
Zhuyubing Fang, Umar Raza, Jia Song, Junyan Lu, Shun Yao, Xiaohong Liu, Wei Zhang, Shujuan Li   +7 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

RAS-challenge as a first-look test for detection of primary aldosteronism in patients with treatment-resistant hypertension

Blood Pressure, 2023
Purpose Primary aldosteronism (PA), characterised by low-renin hypertension, confers a high cardiovascular risk and is the most common cause of secondary hypertension, with an increased prevalence in patients with treatment-resistant hypertension ...
Christian Beger, Theresa Karg, Jan B. Hinrichs, Bastian Ringe, Hermann Haller, Bernhard C. Meyer, Florian P. Limbourg   +6 more
doaj   +1 more source

Amiloride enhances the secretion but not the synthesis of renin in renal juxtaglomerular cells [PDF]

, 1991
In this study we have examined a potential role of the sodium/proton exchange system in the regulation of renin secretion. We found that the inhibitors of the Na+/H+ antiport, amiloride (1 mM) and ethylisopropylamiloride (EIPA, 50 microM), led to a 125 ...
Scholz, Holger, Kurtz, Armin, Della Bruna, R., Baier, Wolfgang   +3 more
core   +1 more source